Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cyclacel Pharmaceuticals Inc is a biotechnology business based in the US. Cyclacel Pharmaceuticals shares (CYCC) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.13 |
|---|---|
| 52-week range | $3.15 - $11.42 |
| 50-day moving average | $3.97 |
| 200-day moving average | $5.46 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.66 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.13 from 2022-01-21
| 1 week (2022-01-13) | -14.25% |
|---|---|
| 1 month (2021-12-23) | -21.75% |
| 3 months (2021-10-22) | -37.77% |
| 6 months (2021-07-23) | -42.99% |
| 1 year (2021-01-22) | -57.87% |
|---|---|
| 2 years (2020-01-24) | 310.49% |
| 3 years (2019-01-24) | 334.12% |
| 5 years (2017-01-24) | 4.96 |
| Revenue TTM | $150,000 |
|---|---|
| Gross profit TTM | $-4,759,000 |
| Return on assets TTM | -33.88% |
| Return on equity TTM | -49.84% |
| Profit margin | 0% |
| Book value | $4.22 |
| Market capitalisation | $36.1 million |
TTM: trailing 12 months
We're not expecting Cyclacel Pharmaceuticals to pay a dividend over the next 12 months.
Cyclacel Pharmaceuticals's shares were split on a 1:20 basis on 14 April 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cyclacel Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cyclacel Pharmaceuticals shares which in turn could have impacted Cyclacel Pharmaceuticals's share price.
Over the last 12 months, Cyclacel Pharmaceuticals's shares have ranged in value from as little as $3.15 up to $11.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyclacel Pharmaceuticals's is 1.1384. This would suggest that Cyclacel Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cyclacel Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.